Anteris Technologies Ltd (ASX: AVR) Share Price and News
Price
Movement
52 Week Range
-
1 Year Return
(20 mins delayed)
() Chart and Price Data
Share Price
Previous Close
Volume
Day Change
Open
Monthly Average Volume
52 Week Range
-
Days Range
-
Turnover
Fundamental Company Figures
Data provided by Morningstar.
Market Cap
$61.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Shares Outstanding
6.57 million
Earnings per share
-0.040
Dividend per share
N/A
Year To Date Return
121.87%
Earnings Yield
N/A
Franking
N/A
Anteris Technologies Ltd (ASX: AVR) Latest News
Why the Anteris Technologies (ASX:AVR) share price soared 23% today
Marc Sidarous | February 24, 2021 4:23pm
Why the Anteris (ASX:AVR) share price will be on watch today
Aaron Teboneras | February 19, 2021 9:52am
Why the Anteris (ASX:AVR) share price is edging higher today
Aaron Teboneras | November 10, 2020 2:28pm
Twiggy Forrest backed Invex Therapeutics has now doubled since its IPO
Tom Richardson | July 5, 2019 2:56pm
Why the Admedus share price is sinking again on more big losses
Tom Richardson | January 21, 2019 4:19pm
Insider share buying can’t stop the Starpharma share price sliding again today
Tom Richardson | December 28, 2018 1:11pm
Recent Stock Announcements
Price Sensitive OnlyAn announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Show All
| Date | Heading | An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security. | Time | Pages | File Size |
|---|---|---|---|---|---|
About Anteris Technologies Ltd (ASX: AVR)
Formerly known as Admedus Ltd (ASX: AHZ), Anteris Technologies Ltd (ASX: AVR) is a healthcare company specialising in the design and production of heart valve and tissue products.
After having sold the rights to its CardioCel® and VascuCel® patch products in 2019, the company’s main focus today is on its Adapt® BioScaffold products and the development of new heart valve replacement solutions. According to Anteris, the Adapt products are used across more than 135 medical centres globally.
In 2020, the company commenced human trials of its DurAVR™ heart valve.
The Anteris share price has been a highly disappointing performer on the ASX, losing more than 90% of its value over the past five years. The company has executed several capital raisings and has struggled with debt and cash flow issues.
Share Price History
Data provided by Morningstar.| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 05 Mar 2021 | $9.40 | $0.40 | 4.44% | 27,812 | $9.40 | $9.50 | $9.01 |
| 04 Mar 2021 | $9.00 | $0.68 | 8.17% | 12,398 | $8.40 | $9.00 | $8.40 |
| 03 Mar 2021 | $8.32 | $-0.67 | -7.45% | 17,849 | $8.90 | $8.90 | $8.20 |
| 02 Mar 2021 | $8.99 | $1.39 | 18.29% | 45,649 | $7.75 | $9.34 | $7.71 |
| 01 Mar 2021 | $7.60 | $0.49 | 6.89% | 10,368 | $7.23 | $7.70 | $7.23 |
| 26 Feb 2021 | $7.11 | $-0.11 | -1.52% | 23,380 | $7.22 | $7.70 | $6.70 |
| 25 Feb 2021 | $7.22 | $0.57 | 8.57% | 40,047 | $6.70 | $7.60 | $6.64 |
| 24 Feb 2021 | $6.65 | $1.13 | 20.47% | 31,003 | $5.85 | $6.86 | $5.66 |
| 23 Feb 2021 | $5.52 | $0.12 | 2.22% | 13,835 | $5.41 | $5.90 | $5.41 |
| 22 Feb 2021 | $5.40 | $0.20 | 3.85% | 33,141 | $5.20 | $5.80 | $5.20 |
| 19 Feb 2021 | $5.20 | $0.20 | 4.00% | 12,905 | $5.13 | $5.20 | $5.00 |
| 18 Feb 2021 | $5.00 | $-0.20 | -3.85% | 5,672 | $5.20 | $5.21 | $5.00 |
| 17 Feb 2021 | $5.20 | $-0.04 | -0.76% | 14,769 | $5.24 | $5.30 | $5.20 |
| 16 Feb 2021 | $5.24 | $0.22 | 4.38% | 7,273 | $5.18 | $5.24 | $5.03 |
| 15 Feb 2021 | $5.02 | $0.32 | 6.81% | 39,316 | $5.05 | $5.25 | $5.00 |
| 12 Feb 2021 | $4.70 | $0.01 | 0.21% | 3,057 | $4.70 | $4.75 | $4.65 |
| 11 Feb 2021 | $4.69 | $0.14 | 3.08% | 3,277 | $4.56 | $4.75 | $4.56 |
| 10 Feb 2021 | $4.55 | $0.13 | 2.94% | 6,366 | $4.47 | $4.59 | $4.43 |
| 09 Feb 2021 | $4.42 | $0.02 | 0.45% | 2,326 | $4.42 | $4.47 | $4.41 |
| 08 Feb 2021 | $4.40 | $0.09 | 2.09% | 4,946 | $4.40 | $4.50 | $4.38 |
| 05 Feb 2021 | $4.31 | $-0.34 | -7.31% | 19,893 | $4.65 | $4.75 | $4.25 |
| 04 Feb 2021 | $4.65 | $-0.16 | -3.33% | 15,358 | $4.80 | $4.81 | $4.55 |
| 03 Feb 2021 | $4.81 | $0.01 | 0.21% | 3,490 | $4.80 | $4.90 | $4.80 |
Director Transactions
Data provided by Morningstar.Directors & Management
Data provided by Morningstar.
Show more
Top Share Holders
Data provided by Morningstar.| Name | Shares | Capital |
|---|---|---|
| Constellation Intl Holdings Limited | 730,192 | 12.35% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 652,219 | 11.04% |
| Constellation Immunotherapy Limited | 402,093 | 6.80% |
| National Nominees Limited <Db A/C> | 373,228 | 6.31% |
| HSBC Custody Nominees (Australia) Limited Gsco Eca | 290,293 | 4.91% |
| Star Bright Holding Limited | 173,680 | 2.94% |
| Merrill Lynch (Australia) Nominees Pty Limited <Mlpro A/C> | 169,733 | 2.87% |
| J P Morgan Nominees Australia Pty Limited | 87,768 | 1.48% |
| Citicorp Nominees Pty Limited | 84,369 | 1.43% |
| Mr Patrick Chew | 73,670 | 1.25% |
| Dr Abdul Ahad Khan | 36,895 | 0.62% |
| Mr Daniel Bernard Clough | 33,584 | 0.57% |
| Through2 Investments Pty Ltd <Through2 Super Fund A/C> | 33,000 | 0.56% |
| Mr Roger Anthony Pierce | 32,673 | 0.55% |
| Bulldog Shale Pty Ltd <Bulldog Shale S Fund A/C> | 30,000 | 0.51% |
| Carron Services Limited | 28,572 | 0.48% |
| Mr Joseph John Doyle and Mrs Cheryl Anne Doyle | 23,527 | 0.40% |
| Mr Athanasios Farmakis | 23,000 | 0.39% |
| Zcsf Nominees Pty Ltd <Zoeller Superfund A/C> | 20,505 | 0.35% |
| Mr Dale Anthony Reed | 20,000 | 0.34% |
| Appwam Pty Ltd | 20,000 | 0.34% |
| Mrs Janet Louise Bowtell and Mr Gary Owen Bowtell <Bowtell Super Fund A/C> | 20,000 | 0.34% |